Celldex jumps on interim Phase II glioblastoma data

Celldex Therapeutics Inc. (NASDAQ:CLDX) was up $4.09 (29%) to $18.25 on Monday after it said rindopepimut ( CDX-110) increased progression-free survival at 6 months, the primary endpoint, and showed an overall survival benefit in the preliminary results of the Phase II ReACT trial to treat recurrent EGFRvIII-positive glioblastoma.

The randomized study comprised three groups. Group 1 compared rindopepimut plus Avastin bevacizumab to the control arm using keyhole limpet hemocyanin (KLH) plus bevacizumab in bevacizumab-naive patients. ...